|
1
|
Vasquez L, Tarrillo F, Oscanoa M, Maza I,
Geronimo J, Paredes G, Silva JM and Sialer L: Analysis of
prognostic factors in high-grade osteosarcoma of the extremities in
children: A 15-year single-institution experience. Front Oncol.
6:222016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gordon N and Kleinerman ES: Aerosol
therapy for the treatment of osteosarcoma lung metastases:
Targeting the Fas/FasL pathway and rationale for the use of
gemcitabine. J Aerosol Med Pulm Drug Deliv. 23:189–196. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferguson WS and Goorin AM: Current
treatment of osteosarcoma. Cancer Invest. 19:292–315. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Broadhead ML, Clark JC, Myers DE, Dass CR
and Choong PF: The molecular pathogenesis of osteosarcoma: A
review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Safadi FF, Xu J, Smock SL, Rico MC, Owen
TA and Popoff SN: Cloning and characterization of osteoactivin, a
novel cDNA expressed in osteoblasts. J Cell Biochem. 84:12–26.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maric G, Rose AA, Annis MG and Siegel PM:
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and
emerging therapeutic target in cancer. Onco Targets Ther.
6:839–852. 2013.PubMed/NCBI
|
|
7
|
Rose AA, Annis MG, Dong Z, Pepin F,
Hallett M, Park M and Siegel PM: ADAM10 releases a soluble form of
the GPNMB/Osteoactivin extracellular domain with angiogenic
properties. PLoS One. 5:e120932010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singh M, Del Carpio-Cano F, Belcher JY,
Crawford K, Frara N, Owen TA, Popoff SN and Safadi FF: Functional
roles of osteoactivin in normal and disease processes. Crit Rev
Eukaryot Gene Expr. 20:341–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rose AA and Siegel PM: Osteoactivin/HGFIN:
Is it a tumor suppressor or mediator of metastasis in breast
cancer? Breast Cancer Res. 9:4032007. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maric G, Annis MG, Dong Z, Rose AA, Ng S,
Perkins D, MacDonald PA, Ouellet V, Russo C and Siegel PM: GPNMB
cooperates with neuropilin-1 to promote mammary tumor growth and
engages integrin α5β1 for efficient breast cancer metastasis.
Oncogene. 34:5494–5504. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhuo H and Zhou L: Gpnmb/osteoactivin: An
indicator and therapeutic target in tumor and nontumorous lesions.
Pharmazie. 71:555–561. 2016.PubMed/NCBI
|
|
12
|
Williams MD, Esmaeli B, Soheili A,
Simantov R, Gombos DS, Bedikian AY and Hwu P: GPNMB expression in
uveal melanoma: A potential for targeted therapy. Melanoma Res.
20:184–190. 2010.PubMed/NCBI
|
|
13
|
Fiorentini C, Bodei S, Bedussi F, Fragni
M, Bonini SA, Simeone C, Zani D, Berruti A, Missale C, Memo M, et
al: GPNMB/OA protein increases the invasiveness of human metastatic
prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9
activity. Exp Cell Res. 323:100–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oyewumi MO, Manickavasagam D, Novak K,
Wehrung D, Paulic N, Moussa FM, Sondag GR and Safadi FF:
Osteoactivin (GPNMB) ectodomain protein promotes growth and
invasive behavior of human lung cancer cells. Oncotarget.
7:13932–13944. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Halim A, Bagley RG and Keler T: Abstract
5032: Glycoprotein NMB (gpNMB) overexpression is prevalent in human
cancers: Pancreatic cancer, non-small cell lung cancer, head and
neck cancer, and osteosarcoma. Cancer Res. 76:5032. 2016.
View Article : Google Scholar
|
|
16
|
Ludwig JA, Lamhamedi-Cherradi SE, Lee HY,
Naing A and Benjamin R: Dual targeting of the insulin-like growth
factor and collateral pathways in cancer: combating drug
resistance. Cancers. 3:3029–3054. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ke M, Mo L, Li W, Zhang X, Li F and Yu H:
Ubiquitin ligase SMURF1 functions as a prognostic marker and
promotes growth and metastasis of clear cell renal cell carcinoma.
FEBS Open Bio. 7:577–586. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yuan TL and Cantley LC: PI3K pathway
alterations in cancer: Variations on a theme. Oncogene.
27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Y, Bi T, Dai W, Wang G, Qian L, Shen G
and Gao Q: Lupeol induces apoptosis and cell cycle arrest of human
osteosarcoma cells through PI3K/AKT/mTOR pathway. Technol Cancer
Res Treat. 15:NP16–NP24. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ono Y, Tsuruma K, Takata M, Shimazawa M
and Hara H: Glycoprotein nonmetastatic melanoma protein B
extracellular fragment shows neuroprotective effects and activates
the PI3K/Akt and MEK/ERK pathways via the
Na+/K+-ATPase. Sci Rep. 6:232412016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu H, Wu Y, Zheng W and Lu S: CO-029 is
overexpressed in gastric cancer and mediates the effects of EGF on
gastric cancer cell proliferation and invasion. Int J Mol Med.
35:798–802. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen L, Wang Q, Wang GD, Wang HS, Huang Y,
Liu XM and Cai XH: miR-16 inhibits cell proliferation by targeting
IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma. FEBS
Lett. 587:1366–1372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Boniface K, Bernard FX, Garcia M, Gurney
AL, Lecron JC and Morel F: IL-22 inhibits epidermal differentiation
and induces proinflammatory gene expression and migration of human
keratinocytes. J Immunol. 174:3695–3702. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Sun Y, Wu Y and Zhang J:
Cucurbitacin E inhibits osteosarcoma cells proliferation and
invasion through attenuation of PI3K/AKT/mTOR signaling. Biosci
Rep: BSR20160165. 2016. View Article : Google Scholar
|
|
25
|
Hu K, Dai HB and Qiu ZL: mTOR signaling in
osteosarcoma: Oncogenesis and therapeutic aspects (Review). Oncol
Rep. 36:1219–1225. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang XJ, Yu HY, Cai YJ and Ke M: Lycium
barbarum polysaccharides inhibit proliferation and migration of
bladder cancer cell lines BIU87 by suppressing Pi3K/AKT pathway.
Oncotarget. 8:5936–5942. 2017.PubMed/NCBI
|
|
27
|
Kolb EA, Gorlick R, Billups CA, Hawthorne
T, Kurmasheva RT, Houghton PJ and Smith MA: Initial testing (stage
1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical
testing program. Pediatr Blood Cancer. 61:1816–1821. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Roth M, Barris DM, Piperdi S, Kuo V,
Everts S, Geller D, Houghton P, Kolb EA, Hawthorne T, Gill J and
Gorlick R: Targeting glycoprotein NMB with antibody-drug conjugate,
glembatumumab vedotin, for the treatment of osteosarcoma. Pediatr
Blood Cancer. 63:32–38. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rose AA, Grosset AA, Dong Z, Russo C,
Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park
M, et al: Glycoprotein nonmetastatic B is an independent prognostic
indicator of recurrence and a novel therapeutic target in breast
cancer. Clin Cancer Res. 16:2147–2156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Torres C, Linares A, Alejandre MJ,
Palomino-Morales R, Martin M, Delgado JR, Martinez J and Perales S:
The potential role of the glycoprotein osteoactivin/glycoprotein
nonmetastatic melanoma protein B in pancreatic cancer. Pancreas.
44:302–310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Le B, Powers GL, Tam YT, Schumacher N,
Malinowski RL, Steinke L, Kwon G and Marker PC: Multi-drug loaded
micelles delivering chemotherapy and targeted therapies directed
against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
PloS One. 12:e01746582017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu M, Bamodu OA, Huang WC, Zucha MA, Lin
YK, Wu ATH, Huang CC, Lee WH, Yuan CC, Hsiao M, et al:
4-Acetylantroquinonol B suppresses autophagic flux and improves
cisplatin sensitivity in highly aggressive epithelial cancer
through the PI3K/Akt/mTOR/p70S6K signaling pathway. Toxicol Appl
Pharmacol. 325:48–60. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rodon J, Dienstmann R, Serra V and
Tabernero J: Development of PI3K inhibitors: Lessons learned from
early clinical trials. Nat Rev Clin Oncol. 10:143–153. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li X, Sun X, Wu J and Li Z: MicroRNA-613
suppresses proliferation, migration and invasion of osteosarcoma by
targeting c-MET. Am J Cancer Res. 6:2869–2879. 2016.PubMed/NCBI
|
|
35
|
Song R, Tian K, Wang W and Wang L: P53
suppresses cell proliferation, metastasis, and angiogenesis of
osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway. Int J
Surg. 20:80–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Keremu A, Maimaiti X, Aimaiti A, Yushan M,
Alike Y, Yilihamu Y and Yusufu A: NRSN2 promotes osteosarcoma cell
proliferation and growth through PI3K/Akt/MTOR and Wnt/β-catenin
signaling. Am J Cancer Res. 7:565–573. 2017.PubMed/NCBI
|
